miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1.

Jian CM et al. Pathol Res Pract. 2018 Sep. doi: 10.1016/j.prp.2018.07.025. [Epub 2018 Jul 27]

Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation‑dependent apoptosis.

Zeng C et al. Oncol Rep. 2018 Sep. doi: 10.3892/or.2018.6544. [Epub 2018 Jul 4]

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.

Yang L et al. Protein Cell. 2018 Sep. doi: 10.1007/s13238-017-0500-9.

DNA damage response-initiated cytokine secretion in bone marrow stromal cells promotes chemoresistance of myeloma cells.

Tang H et al. Leuk Lymphoma. 2018 Sep. doi: 10.1080/10428194.2017.1413188.

Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.

Rotolo A et al. Leuk Lymphoma. 2018 Sep. doi: 10.1080/10428194.2017.1403024.

LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.

Xiao G et al. Exp Cell Res. 2018 Sep 15. doi: 10.1016/j.yexcr.2018.06.026.

Pharmacologic inhibition of AKT leads to cell death in relapsed multiple myeloma.

Song IS et al. Cancer Lett. 2018 Sep 28. doi: 10.1016/j.canlet.2018.06.020.